Pages that link to "Q37687595"
Jump to navigation
Jump to search
The following pages link to Prognostic value of PDL1 expression in pancreatic cancer (Q37687595):
Displaying 28 items.
- Immunodeficiency in Pancreatic Adenocarcinoma with Diabetes Revealed by Comparative Genomics (Q38690307) (← links)
- Prognostic value of PD-L1 overexpression for pancreatic cancer: evidence from a meta-analysis (Q43058997) (← links)
- Ex Vivo PD-L1/PD-1 Pathway Blockade Reverses Dysfunction of Circulating CEA-Specific T Cells in Pancreatic Cancer Patients. (Q45941281) (← links)
- Validation and comparison of the molecular classifications of pancreatic carcinomas (Q46100186) (← links)
- Interleukin 6 Present in Inflammatory Ascites from Advanced Epithelial Ovarian Cancer Patients Promotes Tumor Necrosis Factor Receptor 2-Expressing Regulatory T Cells (Q47121377) (← links)
- PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas. (Q52682430) (← links)
- Strategies for Increasing Pancreatic Tumor Immunogenicity. (Q52691832) (← links)
- CMTM6 stabilizes PD-L1 expression and refines its prognostic value in tumors. (Q54981008) (← links)
- A New Paradigm for Tissue Diagnostics: Tools and Techniques to Standardize Tissue Collection, Transport, and Fixation. (Q55322794) (← links)
- Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences (Q57191808) (← links)
- Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer (Q58086861) (← links)
- Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer (Q58595922) (← links)
- Crosstalk between the Tumor Microenvironment and Immune System in Pancreatic Ductal Adenocarcinoma: Potential Targets for New Therapeutic Approaches (Q60950025) (← links)
- Defective Localization With Impaired Tumor Cytotoxicity Contributes to the Immune Escape of NK Cells in Pancreatic Cancer Patients (Q64063175) (← links)
- Magnetic resonance imaging monitoring therapeutic response to dendritic cell vaccine in murine orthotopic pancreatic cancer models (Q64072891) (← links)
- Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma (Q64090632) (← links)
- POLE Score: a comprehensive profiling of programmed death 1 ligand 1 expression in pancreatic ductal adenocarcinoma (Q64114324) (← links)
- Advances in pancreatic cancer biomarkers (Q64233995) (← links)
- Programmed cell death ligand-1 protein expression and CD274/PD-L1 gene amplification in colorectal cancer: Implications for prognosis (Q89290569) (← links)
- Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer (Q89685705) (← links)
- Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma (Q89727168) (← links)
- Therapies Targeting the Tumor Stroma and the VEGF/VEGFR Axis in Pancreatic Ductal Adenocarcinoma: a Systematic Review and Meta-Analysis (Q90655994) (← links)
- Pancreatic Adenocarcinoma: Unconventional Approaches for an Unconventional Disease (Q90710469) (← links)
- PD-L1 regulates tumorigenesis and autophagy of ovarian cancer by activating mTORC signaling (Q91678519) (← links)
- The prognostic significance of pdl1 and foxp3 expressions in tumor cells and the tumor microenvironment of ovarian epithelial tumors (Q92715349) (← links)
- Contemporary management of borderline resectable pancreatic ductal adenocarcinoma (Q92931846) (← links)
- BioTarget: A Computational Framework Identifying Cancer Type Specific Transcriptional Targets of Immune Response Pathways (Q92948487) (← links)
- Overview of current targeted therapy in gallbladder cancer (Q100490609) (← links)